Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05766592 · ClinicalTrials.gov registry record · Phase 3

Affirmative Family and Individual Psychotherapy for Sexual and Gender Minority Adults and Their Nonaccepting Parents

A Phase 3 study of Mental Health Issue and Parent-Child Relations, sponsored by Yale University.

Recruiting
Registry status
Phase 3
Development phase
124
Enrollment target
2
Study locations

NCT05766592: Recruiting Phase 3 study of Mental Health Issue and Parent-Child Relations, sponsored by Yale University.

NCT05766592 is a Phase 3 study of Mental Health Issue and Parent-Child Relations that is actively recruiting participants, run by Yale University. The registered enrollment target is 124 participants, below the 2,945-participant average among 52 other Mental Health Issue trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05766592, a Phase 3 study of Mental Health Issue and Parent-Child Relations, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 3
Development phase
124 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to assess the efficacy of an LGBTQ-affirmative individual cognitive behavioral psychotherapy (CBT) and LGBTQ-affirmative family therapy (attachment-based family therapy for sexual and gender minority young adults; ABFT-SGM) delivered via telehealth to a sample of sexual and gender minority adults with nonaccepting parent(s) in New York, Pennsylvania, Connecticut, and Israel. The investigators will assess whether both treatments are associated with significant decreases in depressive and anxiety symptoms. The investigators will also assess whether and how each treatment achieves reductions in mental health symptoms through specific mechanisms (e.g., rejection sensitivity, internalized stigma, emotion dysregulation, parental rejection and acceptance).

Primary Outcome

Depressive symptoms will be measured using the 21-item Beck Depression Inventory-II (BDI). Items are rated on a scale from 0-3 where higher scores indicate greater depression symptoms, with a maximum score of 63.

Interventions

  • BEHAVIORAL LGBTQ-affirmative CBT
  • BEHAVIORAL ABFT-SGM

Study Locations (2)

New York

  • Yale LGBTQ Mental Health Initiative with the Yale School of Public Health Office - New York

Other

  • Ben-Gurion University Psychotherapy Research Lab - Beersheba

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2024-08-13
Est. Completion 2027-06-30
Phase Phase 3
Yale University

1,492 total trials

What NCT05766592 shows while recruiting

NCT05766592 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 2,945-participant average among 52 other Mental Health Issue trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Mental Health Issue appearing as the primary indexed condition, and to 2 interventions - of which LGBTQ-affirmative CBT is the first listed.

NCT05766592 reports a single indexed study location in New York, Other.

Frequently Asked Questions

What is clinical trial NCT05766592 about?

NCT05766592 is a clinical study titled "Affirmative Family and Individual Psychotherapy for Sexual and Gender Minority Adults and Their Nonaccepting Parents". The purpose of this study is to assess the efficacy of an LGBTQ-affirmative individual cognitive behavioral psychotherapy (CBT) and LGBTQ-affirmative family therapy (attachment-based family therapy for sexual and gender minority young adults; ABFT-SGM) delivered via telehealth to a sample of sexual ...

What is the current status of trial NCT05766592?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2024-08-13. Estimated completion is 2027-06-30.

What conditions does trial NCT05766592 study?

This clinical trial studies the following conditions: Mental Health Issue, Parent-Child Relations.

What interventions are being tested in trial NCT05766592?

The interventions under investigation include: LGBTQ-affirmative CBT (BEHAVIORAL), ABFT-SGM (BEHAVIORAL).

Who is sponsoring clinical trial NCT05766592?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05766592 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mental Health Issue

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05766592's enrollment target sits among peer trials

124 29th of 52 higher than 24 of 52 other Mental Health Issue trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mental Health Issue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523014 · 124 participants · Phase 2

    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • NCT02670707 · 124 participants · Phase 3

    Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

  • NCT02830724 · 124 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • NCT04748809 · 124 participants · NA

    Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05766592, the US trial registry maintained by the National Library of Medicine. NCT05766592 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.